所謂飆股，就是美債殖利率破5%也沒在怕，開盤照樣漲給你看，諾和諾德（Novo Nordisk）就是這樣一檔股票。 細探歷史，發現諾和諾德原來創業正好滿100年，該公司多年來一直是全世界胰島素產品的霸主，但最近幾年，它推出的GLP-1藥物除了幫助第二型糖尿病患者控制血糖，也因為有減重效果大受歐美人士歡迎，馬斯克都發推文介紹自己是在wegovy藥物幫助下成功瘦身。究竟諾和諾德如何站穩糖尿病市場，為什麼這款藥物又會成為減肥神藥？以下是本集節目重點整理：2023年，LVMH市值被它正式超越專注糖尿病治療100年的諾和諾德當一款藥物被大眾強力追捧甚至號稱「減肥仙丹」，接下來會發生什麼？ 小額贊助支持本節目： https://open.firstory.me/user/ckjxnwzo58elm0989tt6w3bf4 留言告訴我你對這一集的想法： https://open.firstory.me/user/ckjxnwzo58elm0989tt6w3bf4/comments Powered by Firstory Hosting
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
Trump $82 Million Bond Spree, Brazil Tariffs 'Too High,' More
16 Nov 2025
Bloomberg News Now
Ex-Fed Gov Resigned After Rules Violations, Trump Buys $82 Mil of Bonds, More
16 Nov 2025
Bloomberg News Now
THIS TRUMP INTERVIEW WAS INSANE!
16 Nov 2025
HasanAbi
Epstein Emails and Trump's Alleged Involvement
15 Nov 2025
Conspiracy Theories Exploring The Unseen
New Epstein Emails Directly Implicate Trump - H3 Show #211
15 Nov 2025
H3 Podcast
Trump Humiliates Himself on FOX as They Call Him Out
15 Nov 2025
IHIP News